Literature DB >> 18193083

Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population.

J Abubaker1, P Bavi, S Al-Harbi, M Ibrahim, A K Siraj, N Al-Sanea, A Abduljabbar, L H Ashari, S Alhomoud, F Al-Dayel, S Uddin, K S Al-Kuraya.   

Abstract

Activation of the phosphatidylinositol 3'-kinase (PI3K)/AKT pathway results in an increase in cell proliferation and survival. Somatic mutations within the PI3K catalytic subunit, PIK3CA are common cause of increasing PI3K activity and are believed to be oncogenic in many cancer types. Few reports addressed the association between PIK3CA mutations and tumor progression specifically in microsatellite instable (MSI) colorectal cancer (CRC). In the present study, we have evaluated PIK3CA mutational status in a series of 410 Middle Eastern CRC and 13 colon cell lines to study the prevalence of PIK3CA mutations in MSI cases, PTEN expression in CRC and possibility of therapeutic targeting of this set of patients. PIK3CA mutations were found in four of the cell lines tested and 51 colorectal carcinomas (12.2%). Three of these four mutated cell lines were MSI. PTEN was inactivated in 66.1% of the CRC. Furthermore, we observed a strong association between PIK3CA mutations and MSI status (P=0.0046) while PTEN loss was more frequent in microsatellite stable (MSS) CRC (P=0.043). A high prevalence of genetic alterations in PI3K/AKT pathway in Saudi cohort of CRC, predominance of PIK3CA mutations in the MSI subgroup and their possible involvement in development/progression of this subset of CRC are some of the significant findings of our study.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18193083     DOI: 10.1038/sj.onc.1211013

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  39 in total

Review 1.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

2.  PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.

Authors:  Shuji Ogino; Katsuhiko Nosho; Gregory J Kirkner; Kaori Shima; Natsumi Irahara; Shoko Kure; Andrew T Chan; Jeffrey A Engelman; Peter Kraft; Lewis C Cantley; Edward L Giovannucci; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2009-02-23       Impact factor: 44.544

3.  No association between phosphatase and tensin homolog genetic polymorphisms and colon cancer.

Authors:  Lynette S Phillips; Cheryl L Thompson; Alona Merkulova; Sarah J Plummer; Thomas C Tucker; Graham Casey; Li Li
Journal:  World J Gastroenterol       Date:  2009-08-14       Impact factor: 5.742

4.  Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern.

Authors:  Humaid O Al-Shamsi; Jeremy Jones; Yazan Fahmawi; Ibrahim Dahbour; Aziz Tabash; Reham Abdel-Wahab; Ahmed O S Abousamra; Kenna R Shaw; Lianchun Xiao; Manal M Hassan; Benjamin R Kipp; Scott Kopetz; Amr S Soliman; Robert R McWilliams; Robert A Wolff
Journal:  J Gastrointest Oncol       Date:  2016-12

5.  PIK3CA Somatic Mutation Status in Relation to Patient and Tumor Factors in Racial/Ethnic Minorities with Colorectal Cancer.

Authors:  Amanda I Phipps; Dennis J Ahnen; Iona Cheng; Polly A Newcomb; Aung Ko Win; Terrilea Burnett
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-05-20       Impact factor: 4.254

6.  mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors.

Authors:  Yanjie Zhang; X F Steven Zheng
Journal:  Cell Cycle       Date:  2012-02-01       Impact factor: 4.534

7.  The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type.

Authors:  Stefano Barbi; Ivana Cataldo; Giovanni De Manzoni; Samantha Bersani; Simona Lamba; Silvia Mattuzzi; Alberto Bardelli; Aldo Scarpa
Journal:  J Exp Clin Cancer Res       Date:  2010-04-16

8.  Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway.

Authors:  Eduardo Vilar; Bhramar Mukherjee; Rork Kuick; Leon Raskin; David E Misek; Jeremy M G Taylor; Thomas J Giordano; Samir M Hanash; Eric R Fearon; Gad Rennert; Stephen B Gruber
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

9.  KRAS and TP53 mutations in colorectal carcinoma.

Authors:  Khawla S Al-Kuraya
Journal:  Saudi J Gastroenterol       Date:  2009 Oct-Dec       Impact factor: 2.485

10.  Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer.

Authors:  Shahab Uddin; Rong Bu; Maqbool Ahmed; Jehad Abubaker; Fouad Al-Dayel; Prashant Bavi; Khawla S Al-Kuraya
Journal:  Mol Cancer       Date:  2009-09-18       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.